This triggers audio and visual alerts to the person behind the wheel when the camera detects their eyes are away from the road for dangerous periods of time as a part of a mandated safety requirement for new models under the European Union's latest GSR2 legislation.
While the EU rules do not currently apply for UK-sold models, minsters recently suggested they will be adopted in Britain soon.
£1 a share is a market cap of £70 million. That’s three times revenue. The share price does NOT reflect the real value of TRX. Hardman was suggesting £1.66 share. So £1 is cheap. Very cheap.
extract just published in the european journal of cardiothoracic surgery….
dear editor,
the single-centre retrospective study by andreeva et al. [1] shows a lower mortality rate and higher freedom from valve-related adverse events in young patients who received
aortic ****grafts (dahs) versus mechanical composite valve grafts (mcvgs) up to 5 years after surgery. this study serving the needs of young patients
6000 per month is ok as a new launch but there is no reason why it can’t grow significantly (5-fold). That’s 30,000 a month of over 350,000,000 people.
The share price has been manipulated, it’s clear as day. Price is now ‘ripe’ for an offer. If this doesn’t get bought out for at least £1 a share we’ve been shafted. I hope they get on with it so I can be out of this one asap.